Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Apr 19;16(4):e0250150. doi: 10.1371/journal.pone.0250150

Stillbirth rates, service outcomes and costs of implementing NHS England’s Saving Babies’ Lives care bundle in maternity units in England: A cohort study

Kate Widdows 1, Stephen A Roberts 2, Elizabeth M Camacho 3, Alexander E P Heazell 1,4,*
Editor: Ju Lee Oei5
PMCID: PMC8055032  PMID: 33872334

Abstract

Objective

To assess implementation of the Saving Babies Lives (SBL) Care Bundle, a collection of practice recommendations in four key areas, to reduce stillbirth in England.

Design

A retrospective cohort study of 463,630 births in 19 NHS Trusts in England using routinely collected electronic data supplemented with case note audit (n = 1,658), and surveys of service users (n = 2,085) and health care professionals (n = 1,064). The primary outcome was stillbirth rate. Outcome rates two years before and after the nominal SBL implementation date were derived as a measure of change over the implementation period. Data were collected on secondary outcomes and process outcomes which reflected implementation of the SBL care bundle.

Results

The total stillbirth rate, declined from 4.2 to 3.4 per 1,000 births between the two time points (adjusted Relative Risk (aRR) 0.80, 95% Confidence Interval (95% CI) 0.70 to 0.91, P<0.001). There was a contemporaneous increase in induction of labour (aRR 1.20 (95%CI 1.18–1.21), p<0.001) and emergency Caesarean section (aRR 1.10 (95%CI 1.07–1.12), p<0.001). The number of ultrasound scans performed (aRR 1.25 (95%CI 1.21–1.28), p<0.001) and the proportion of small for gestational age infants detected (aRR 1.59 (95%CI 1.32–1.92), p<0.001) also increased. Organisations reporting higher levels of implementation had improvements in process measures in all elements of the care bundle. An economic analysis estimated the cost of implementing the care bundle at ~£140 per birth. However, neither the costs nor changes in outcomes could be definitively attributed to implementation of the SBL care bundle.

Conclusions

Implementation of the SBL care bundle increased over time in the majority of sites. Implementation was associated with improvements in process outcomes. The reduction in stillbirth rates in participating sites exceeded that reported nationally in the same timeframe. The intervention should be refined to identify women who are most likely to benefit and minimise unwarranted intervention.

Trial registration

The study was registered on (NCT03231007); www.clinicaltrials.gov.

Introduction

Stillbirth, defined in the UK as the death of a baby before birth after 24 weeks’ gestation [1], has been challenging to reduce, with an annual rate of reduction in the UK of 1.4% between 2000 and 2015, placing the UK in the lowest third of high-income countries (HICs) [2]. Analysis of stillbirth rates within the UK demonstrates significant variation between regions, with the highest stillbirth rates seen in some areas of London, Midlands and the North of England [3,4]. The variation between countries and within the UK suggests that improvement in the stillbirth rate is possible [2]. Given the significant psychological, social and economic impact of stillbirth on mothers and their families [5], further reduction in stillbirth rate in the UK is needed.

Evidence suggests that a significant proportion of these deaths are preventable; Confidential Enquiries into normally formed antepartum stillbirths identified deficiencies in care that contributed to this outcome in 60% of cases, rising to 80% in intrapartum-related deaths [6,7]. Risk factors for stillbirth in HICs include: fetal growth restriction, maternal medical co-morbidities (e.g. diabetes, hypertension), cigarette smoking and maternal perception of reduced fetal movements [8]. Deficiencies in the identification and management of these risk factors has been reported in analyses of stillbirths dating back to 1998 [9]. This information provides a starting point for initiatives to reduce stillbirth in the UK.

To address stillbirth rates in the UK, the Department of Health announced a new ambition to halve the rate of stillbirths by 2030, with a 20% reduction by 2020. In response, NHS England introduced the Saving Babies Lives (SBL) care bundle in 2015 which sought to implement recommendations from established national guidance to address specific risk factors for stillbirth, including i) smoking cessation, ii) fetal growth restriction, iii) reduced fetal movements (RFM) and iv) intrapartum hypoxia [10]. The SBL care bundle consisted of 16 recommendations in four areas of practice: Element 1: Reducing smoking in pregnancy (4 components), Element 2: Risk assessment and surveillance for fetal growth restriction (5 components), Element 3: Raising awareness of reduced fetal movements (2 components) and Element 4: Promoting effective fetal monitoring in labour (5 components). In 2016, NHS England commissioned a retrospective evaluation of the implementation of the SBL care bundle, involving extensive consultation with key stakeholders and participating Trusts a protocol was agreed and published [11]. Here we report the primary and secondary outcomes of the evaluation, exploratory outcomes where these aid interpretation, and the results of the economic analysis.

Methods

Design and study population

We conducted a pragmatic analysis before and after the introduction of the SBL care bundle (the exposure of interest) using longitudinal data collected retrospectively in 19 NHS Trusts in England across 9 clinical networks. These trusts were purposively selected from a larger cohort of maternity units that had participated in the 2015 NHS Tracker Survey to provide a geographically distributed sample throughout England and a range of birth rates and levels of neonatal care and to reflect a range of levels of implementation at the time of selection. Units from London were not included as they were participating in a stepped-wedge cluster trial of implementation of the Growth Assessment Protocol [12]. These trusts were deemed early adopters as they were pilot sites for implementing SBL in 2015 ahead of the national launch in March 2016. For the purposes of this analysis April 2015 was defined as the start of implementation in these 19 Trusts and outcomes were assessed at the nominal dates of April 2013 ("before") and April 2017 ("after") respectively, providing a minimum of two years of data before and after implementation of the SBL care bundle.

Retrospective data collection for the period April 2013 to October 2017 was carried out between September 2017 and January 2018. Recruitment (for surveys) took place between August and December 2017, following approval by the Health Research Authority in June 2017 (Reference 17/WM/0197). The study was registered on www.clinicaltrials.gov (NCT03231007) in July 2017 before commencement of data collection, and the evaluation protocol was published before commencing data analysis [11]. Analysis was performed on anonymized data. The study was reported according to STROBE guidelines [13].

Variables and data sources

Definitions of data collection methods and outcomes are described in detail in the protocol [11]. In brief, outcome data was collected from routine electronic clinical data held in Trust data repositories where this was available, the data being provided or converted to monthly aggregate totals (e.g. number of births per month). Anonymised postcode data were used to derive the index of multiple deprivation (IMD) and a mean decile computed for each Trust; where this was not provided an estimate was derived as the mean IMD of a surrounding area based on population size and birth numbers.

This was supplemented by clinical audits (20 sequential women per time point and Trust) of growth and birth monitoring practice in unselected women (pre and post implementation), small for gestational age births (pre and post implementation) and women attending hospital with RFM (post-implementation only). Additionally, in the post intervention period women were asked to complete a survey postpartum prior to discharge (informed consent) which included questions on smoking behaviour and interventions received along with experiences of RFM (S1 File). All health professionals involved in delivering maternity care were invited to participate in an online or paper survey regarding their views and experiences of the SBL care bundle (S2 File) if they had been employed in their current Trust prior to the launch of the care bundle initiative in April 2015. Data on the degree of implementation of the SBL care bundle was self-reported by Trusts and implementation scores were derived by applying a score to a Likert scale whether each intervention in each element was implemented: a) all of the time (score 3), b) most of the time (score 2), c) half of the time (score 1), d) not much of the time (score 0), e) never (score 0), or f) not relevant (score 0). These were totalled to give an implementation score for each element. As there were different numbers of interventions within individual elements, the overall implementation score for each Trust was calculated as the mean of the implementation scores for the four elements, each expressed as a percentage of the maximum score.

Statistical analysis

Electronic data on stillbirths other clinical outcomes and smoking rates was provided as, or converted to, monthly counts of outcomes and appropriate denominators. Outcomes were fitted using quasi-binomial models to allow for the possibility of overdispersion, except for scan rates, which were fitted using quasi-Poisson models. Generalised linear models with logarithmic link functions were used to estimate a linear trend over time. Trust was included as a covariate thus time trends are estimated on a within-Trust basis. From this model we derived estimates of the outcome rates at dates 2 years either side of the nominal SBL start date of April 2015 and estimated the risk- (or rate) ratio between these two time points as a measure of the change over the implementation period. Models additionally containing a step change at the nominal or reported implementation dates were also considered, but proved to be uninformative as step-changes could not be detected and therefore are not presented.

In order to investigate the relationship with reported implementation status, generalised linear mixed models were fitted with Trust as a random intercept and assessment-date implementation level, Care Level (Tertiary v Secondary), IMD (mean decile) and month as fixed effects. A risk-ratio between no and full implementation is reported.

Audit data and women’s questionnaire data were available for one or two time points and the outcomes are presented as proportions of women audited with exact Binomial 95% CI. Where there were data from 2 time points (pre and post implementation), risk ratios between the two time points were derived using binomial regression models with logarithmic link functions. Data analyses were conducted using R (www.R-project.org) [14].

The sample sizes for the various datasets were largely determined pragmatically by the constraints of time and the need to have a reasonable pre and post launch period to assess trends, with an inevitably staggered true implementation. Based on a prevalence of 4.7 normally formed singleton stillbirths per 1,000 total births in 2014 [4], the potential annual number of stillbirths detected was estimated as 470 per 100,000 total births across all study sites. Conservatively, a two year pre versus one year post-comparison was estimated to have 80% power to detect a drop in the primary stillbirth rate from 4.7 to 3.9/1000 –a 17% reduction [11].

Economic analysis

An economic analysis was carried out using the data generated from the comparisons outlined above alongside additional data reported by the Trusts on the resources they used to implement the SBL care bundle and the level of implementation they reported. These data were also used to estimate what annual costs and stillbirths avoided for the whole of England would be in the scenario that all Trusts implemented all elements of SBL care bundle.

The implementation cost consists of two parts: the direct cost of putting in place each element and the cost of the secondary effects (mode of delivery, induction of labour, ultrasound scans). The direct cost of implementing each element was estimated but it is not possible to determine which element the secondary effects relate to so they have been calculated for the SBL care bundle overall. No additional funding was provided to Trusts to implement the SBL therefore the direct implementation costs should be interpreted as the ’value’ of the SBL rather than additional funding required.

Unit costs were derived from published sources [15,16], NHS partners [17], and through email communication with training/software providers. The fees for externally-provided training courses were included in the implementation cost. In-house training was assumed to form part of routine, ongoing continuing professional development (CPD), and so the cost of staff time to complete training was not included in the primary analysis, but was explored in a sensitivity analysis.

The total annual birth rate for England was identified from national published data [18]. The time-series-adjusted stillbirth rates from before and after the implementation date were applied to this number to estimate the difference in the number of stillbirths before and after implementation of the SBL care bundle i.e. the number of stillbirths potentially avoided.

It was necessary to make a number of assumptions in order to estimate the resources and costs associated with the care bundle. As such the costs and outcomes reported should be interpreted as ‘best estimates’. The impact of varying some of the assumptions on costs and outcomes were explored in a series of one-way sensitivity analyses.

Results

The characteristics of the participating Trusts are described in Table 1. The annual birth rate ranged from 2,900 to 8,894. Thirteen out of the 19 Trusts (68%) were secondary care providers with the remainder being tertiary maternity units. The majority (n = 17) of Trusts provided care for women residing in areas between the 2nd and 6th deciles of deprivation. Implementation rates of the SBL care bundle ranged from 0 to 100%, with a mean value of 74%. Response rate on the patient questionnaire was between 9% and 60% of all births.

Table 1. Characteristics of participating trusts.

Trust Care Level Births per year IMD decile Implementation Score (%) Patient Response Rate
A Level 2 6309 3 [25] 100 39/424 (9%)
B Level 2 4859 6 [49] 98 34/241 (14%)
C Level 2 3970 6 [48] 95 99/215 (46%)
D Level 2 2900 3 [26] 93 102/297 (34%)
E Level 2 3300 6 [37]* 78 109/1193 (9%)
F Level 3 5833 6 [47] 90 103/357 (29%)
G Level 2 3808 2 [15] 90 105/407 (26%)
H Level 3 8550 2 [15] 90 74/675 (11%)
I Level 2 4533 7 [59]* 80 135/245 (55%)
J Level 2 3263 5 [47] 80 105/193 (54%)
K Level 2 1816 3 [26] 0 120/290 (41%)
L Level 2 2962 6 [29] 79 161/429 (38%)
M Level 2 3436 4 [26] 75 123/205 (60%)
N Level 3 4207 5 [37] 74 103/571 (18%)
O Level 2 3205 5 [27] 70 170/501 (34%)
P Level 3 8166 8 [69] 56 107/213 (50%)
Q Level 3 8265 2 [15] 61 264/820 (32%)
R Level 3 8894 2 [14] 56 105/887 (12%)
S Level 2 5240 3 [26] 40 113/457 (25%)

Care level (level 2 = secondary, level = 3 tertiary), number of births per year, median and IQR IMD decile [1 = most deprived, 10 = least deprived], SBL implementation at the nominal assessment date and response rate to the patient questionnaire. The overall patient response rate was: 2171/8620 (25%).

*Estimated from geography.

Trusts reported that the SBL care bundle was implemented in a phased and gradual manner, with most Trusts implementing some SBL care bundle elements prior to the SBL launch and 12/19 achieving >75% implementation by the end of the study period. Table 1 shows the implementation scores at the assessment date (April 2017) for each Trust with fuller details of the individual elements and time points available in S1 Fig. Many Trusts were unable to give precise dates for the implementation of individual elements of the SBL care bundle. Implementation rates varied between elements with only one Trust stating 100% for all four elements; intrapartum fetal monitoring was the most completely implemented element of the care bundle and screening for SGA infants the least.

Stillbirth rates

Stillbirth rates declined from 4.2 to 3.4 per 1,000 births over the 4 year period, which was statistically significant (P<0.001), RR of 0.80 (Table 2). Fig 1 shows a steady decline in the rate over time, and we were unable to demonstrate any step changes associated with implementation of the SBL care bundle. Term singleton and stillbirths associated with SGA showed similar decline (Table 2). Pre-term stillbirth showed a slightly smaller decreased from 2.3 per 1,000 births to 1.9 per 1,000 births (Relative Risk 0.82, p = 0.014). We were unable to demonstrate any association between stillbirth rates and the reported level of implementation of the SBL care bundle (Table 2).

Table 2. Clinical and service outcomes.

Post v Pre SBL Full v no implementation *
Trusts Women Pre Post RR P RR P
All Stillbirths 19 463,630 4.2 3.4 0.80 (0.70–0.91) <0.001 1.04 (0.73–1.48) 0.84
Term Singleton Stillbirths 17 387,474 1.6 1.3 0.78 (0.63–0.96) 0.021 1.34 (0.73–2.45) 0.34
Term Singleton SGA Stillbirths 17 387,474 0.6 0.4 0.69 (0.47–1.02) 0.060 0.80 (0.32–1.98) 0.63
Preterm births 15 407,484 7.4 7.9 1.06 (1.03–1.10) <0.001 0.91 (0.70–1.18) 0.47
Preterm Singleton births 16 425,433 6.3 6.6 1.05 (1.02–1.08) 0.002 0.87 (0.64–1.17) 0.36
NICU admissions 11 282,854 3.5 4.1 1.19 (1.11–1.26) <0.001 0.86 (0.061–12.05) 0.91
Emergency CS 15 386,817 13.7 15.0 1.10 (1.07–1.12) <0.001 1.02 (0.84–1.24) 0.85
Elective CS 17 452,944 9.9 11.8 1.19 (1.16–1.23) <0.001 1.01 (0.73–1.38) 0.97
Induction of labour 18 473,889 26.3 31.4 1.20 (1.18–1.21) <0.001 0.92 (0.73–1.14) 0.44
Instrumental Births 18 473,889 12.2 12.4 1.01 (0.99–1.04) 0.25 0.83 (0.64–1.08) 0.17
Spontaneous Births 18 473,889 63.4 60.4 0.95 (0.95–0.96) <0.001 1.00 (0.88–1.15) 0.94
US scans per pregnancy 8 262,386 3.5 4.3 1.25 (1.21–1.28) <0.001 1.42 (0.94–2.17) 0.12

Columns show the number of Trusts and women providing data, the fitted pre and post implementation rates (±2y from the SBL launch date), the post v pre risk ratio (with 95%CI and significance level) and the risk ratio associated with 100% overall SBL care bundle implementation.

* Adjusted for care level, IMD and calendar month.

Fig 1. Average total stillbirth rate across participating sites.

Fig 1

Comparison between pre and post implementation of the Saving Babies Lives care bundle demonstrates a reduction between pre- and post-implementation periods. Republished from Saving Babies’ Lives Project Impact and Results Evaluation (SPiRE): A mixed methodology study under a CC BY license, with permission from the University of Manchester, original copyright 2018.

Changes in secondary outcomes

Table 2 summarises the clinical and service outcomes derived from Trust database systems. There were modest increases in the numbers of preterm births, induction of labour and emergency Caesarean sections (CS) over the evaluation period. The number of ultrasound scans per pregnancy increased markedly from 3.5/pregnancy to 4.3/pregnancy in the 8 Trusts providing complete data (S2 Fig). Other Trusts provided partial scan data which was consistent with these trends, but not sufficiently complete for formal analysis. An increase in the number of ultrasound scans performed was associated with a reduction in stillbirth rate (Adjusted Rate Ratio of -0.14 (SE 0.06) stillbirths per additional scan performed P = 0.026). Increases were also seen in elective CS and admissions to NICU, although it must be noted that the quality of data regarding NICU admission was poor. None of these outcomes showed a significant association with implementation of the SBL care bundle.

Process outcomes

The number of women smoking at delivery declined from 14.3% to 11.8% (P<0.001) over the evaluation period. However, this reflects a decline in the proportion of women smoking at booking rather than an increase in the numbers ceasing smoking during pregnancy (Table 3). 70.1% of women reported being offered a CO test and 99.1% of these women reported accepting the offer, however a smaller proportion of women who smoked were offered referral to smoking cessation services (60.1%) and only 31.0% attended this service. Trusts reporting full implementation of the element had higher proportion of women having a CO test at booking (RR 7.95, Table 3), but no difference in the proportion of women referred for smoking cessation services (RR 1.11, Table 3).

Table 3. Process outcomes.

Post v Pre SBL Full v no implementation *
Source Trusts Women Pre Post RRpost P RR P
Element 1 Smoking Cessation
Smoking at Delivery Women 19 2,085 - 10.1 - - 1.21 (0.67–2.19) 0.50
Smoking at Delivery Electronic Data 14 268,736 14.3 11.8 0.83 (0.80–0.86) <0.001 0.91 (0.44–1.86) 0.80
Offered CO test Women 19 1,870 - 70.1 - - 7.95 (5.17–12.23) <0.001
Referred to smoking cessation Women 19 311 - 60.1 - - 1.11 (0.41–2.98) 0.82
Ceased Smoking Women† 19 331 - 40.8 - - 0.70 (0.28–1.76) 0.42
Ceased Smoking Electronic Data 11 27,550 28.7 27.0 0.94 (0.87–1.01) 0.098 3.99 (0.80–19.99) 0.11
Smoked in Pregnancy Women 19 2,158 - 15.7 - - 1.15 (0.71–1.86) 0.55
Smoking at Booking Electronic Data 11 203,635 16.2 14.1 0.87 (0.84–0.90) <0.001 0.50 (0.25–1.02) 0.070
Element 2 Detection and Management of SGA fetus
SGA detected SGA Audit 17 636 33.8 53.7 1.59 (1.32–1.92) <0.001 1.16 (0.34–4.01) 0.79
Growth chart in records General Audit 18 720 - 97.8 - - 1.21 (0.17–8.80) 0.84
EFW plotted SGA Audit 17 636 24.7 75.7 3.06 (2.48–3.76) <0.001 38.24 (7.80–187.46) <0.001
EFW plotted correctly SGA Audit 17 582 99.2 99.1 1.00 (0.98–1.01) 0.80 Insufficient Data -
SFH plotted SGA Audit 17 636 35.5 47.8 1.35 (1.11–1.63) 0.002 5.07 (1.42–18.11) 0.005
Element 3 Fetal Movements
RFM leaflet received Women 19 1,735 - 74.4 - - 2.87 (1.98–4.17) <0.001
RFM checklist used RFM Audit 17 339 - 52.2 - - 0.44 (0.22–0.88) 0.010
Attendances for RFM Women 19 2,171 - 36.5 - - 0.95 (0.70–1.28) 0.70
Scan after RFM (any) RFM Audit 17 322 - 64.9 - - 0.54 (0.25–1.17) 0.080
Scan for RFM Women 19 793 - 29.4 - - 0.85 (0.49–1.46) 0.52
Heart Monitoring every RFM visit RFM Audit 17 339 - 97.3 - - 0.28 (0.03–2.82) 0.18
Heart Trace for RFM Women† 19 793 - 73.5 - - 0.81 (0.46–1.43) 0.42
Induced following RFM RFM Audit 17 338 - 54.7 - - 4.78 (2.29–9.95) <0.001
Element 4 Fetal Monitoring
Buddy and Sticker used General Audit 18 527 - 50.3 - - 33.00 (10.85–100.39) <0.001
Escalation Protocol used General Audit 18 224 - 98.7 - - Insufficient Data -

Columns show the data source, the number of Trusts and women providing data, the fitted pre and* post implementation rates (±2y from the SBL launch date), the post v pre risk ratio (with 95% CI and significance level) and the risk ratio associated with 100% implementation of the relevant SBL element.

* Adjusted for care level, IMD and calendar month.

†Women–refers to data obtained via the postnatal questionnaire of women undertaken in the postnatal period.

Over the time period of the evaluation, documentation of screening for SGA fetuses improved, with increased documentation of symphysis-fundal height and estimated fetal weight on fetal growth charts. The documentation of these parameters was also significantly higher in Trusts with full implementation of this element (RR 5.07 (symphysis-fundal height), RR 38.24 (estimated fetal weight)). The documented increase in screening for SGA fetuses and in the frequency of ultrasound scan was associated with a 59% increase in the detection rate of SGA fetuses from 33.8% to 53.7% (Table 3). The leaflet regarding RFM was reported to be received by the majority of women (73.1%), and attendance with RFM occurred in 77.3% of episodes of RFM. A lower proportion of cases used a checklist to guide management (52.2%) and management varied from practice recommended in SBL care bundle with 74.4% of women with RFM having a fetal heart rate tracing and 29.4% of women receiving an ultrasound scan. A large proportion of women reporting RFM had an induction of labour (54.7%; Table 3). Women attending trusts with full implementation of the SBL care bundle were more likely to receive the information leaflet about RFM (RR 2.87, Table 3).

We were unable to obtain sufficient data directly from participating Trusts regarding training in interpretation of fetal heart rate traces over the duration of implementation of the SBL care bundle. Data from the staff questionnaires showed that 56.5% of staff (n = 1,064) reported they had received training in the preceding year with 16.8% of those who had been trained reporting they had completed assessment in fetal heart rate interpretation. Staff employed the “buddy system” where at least two professionals interpreted the fetal heart rate trace in 50.2% of audited cases. Trusts with full implementation were more likely to have used the CTG “buddy system” and a standardised recording of the fetal heart rate assessment (RR 33.00).

Staff views

1,064 health professionals completed the staff survey (details of respondents can be found in S3 File); 78% of respondents were midwives. Overall, 58% (584/905) of respondents were aware of the SBL care bundle, with lowest rates of awareness in junior doctors and ultrasonographers (47% (7/15) and 32% (11/34) of respondents respectively). Almost all staff perceived an increased demand for ultrasound scans (97%, Table 4), rates of induction of labour (98%) and to a lesser extent Caesarean sections (80%). A significant proportion of respondents (41%) perceived that the stillbirth rate had decreased in their unit, although the same proportion perceived it was unchanged (Table 4). Most staff 82% (807/983) agreed with the statement that their unit was actively doing things to improve the safety of mothers and babies.

Table 4. Staff views about changes in practice and outcomes in their Trust over the time frame of adoption of the SBL care bundle (n = 1,064).

Over the last 5 years Greatly increased Slightly increased Not changed Slightly decreased Greatly decreased Don’t know
The demand on ultrasound scanning has… 839 (87%) 98 (10%) 15 (2%) 2 (0%) 11 (1%) 99
The number of stillbirths has… 10 (1%) 126 (16%) 323 (41%) 260 (33%) 65 (8%) 280
The number of babies admitted to a NICU has… 108 (15%) 330 (47%) 214 (30%) 47 (7%) 5 (1%) 360
The number of inductions… 713 (79%) 171 (19%) 17 (2%) 4 (0%) 1 (0%) 158
The number of caesarean sections has… 270 (31%) 425 (49%) 161 (18%) 13 (1%) 2 (0%) 193

Percentages calculated as proportion of those who expressed a view regarding the statement.

Economic analysis

There were 666,025 births (live births and stillbirths) in England in 2016 [18]. Based on data observed from the study sites, the number of women booked is on average 14% higher than the number of births, therefore, it was estimated that there were 759,299 bookings in the same period. The primary estimated cost of implementing the care bundle for the first year in England is £93,116,650, or approximately £140 per birth. The direct cost (excluding secondary costs) is £3,650,357 (4%) of the total cost. The full breakdown of costs are reported in Table 5.

Table 5. Estimated annual costs for England associated with the SBL care bundle.

A. Direct implementation cost
Element Resources included Resources excluded Cost (£)
Element 1 i. 9 CO monitors/1000 births (£165 each)
ii. D-pieces for monitors, to be replace monthly (£3 each)
iii. Mouthpieces for monitors, one per each woman booked (£0.25 each)
i. 10 minutes of midwife time to speak to women who smoke (9–24% of women in study) about smoking cessation and/or do referral
ii. Calibration of monitors
£1,394,713
Element 2* i. GAP software set-up (£500/Trust)
ii. GAP annual software cost (£1500–5000 depending on size of Trust)
i. Staff time (midwives and sonographers) to attend training course in GAP software run for free by Perinatal Institute
ii. Administrator time to generate customised growth charts
£391,000
Element 3 i. Trusts instructed to add logos to leaflet and then photocopy from a master copy, two sides of A4 (£0.10 each) i. Midwife time to discuss leaflet
ii. Midwife time to discuss RFM at subsequent visits
iii. Attendances with perceived RFM
£66,605
Element 4 i. Online training course in CTG interpretation (£60) completed annually by midwives, consultants, and junior doctors i. Staff time to complete training course £1,798,039
Direct Cost £3,650,357 (4% of total cost)
B. Secondary implementation costs
Inductions Induction rate increased from 26.27 to 31.40 per 100 births, costing £847.15 per induction. £28,945,817 (31% of total cost)
Births Before After Cost £26,754,741 (29% of total cost)
Normal (£1704.50) 63.42 61.94b -£16,802,227
EMCS (£4553.41) 13.69 15.01 £40,033,063
Instrumental (£3306.71) 12.25 12.41 £3,523,905
Scans Number of scans per woman booked increased from 3.51 to 4.35 (24% increase), costing £52.94 per scan. £33,765,735 (36% of total cost)
Secondary costs £89,466,293 (96% of total cost)
TOTAL £93,116,650

EMCS = emergency Caesarean section; *although the use of GROW software to generate customised growth charts was not specified in the care bundle, only 2 out of 19 Trusts included in the analysis said that they did not use it therefore it was included in the costs.

A series of one-way sensitivity analyses were conducted to explore the impact of assumptions made to estimate costs. Selected sensitivity analyses are shown in Table 6 below (see S1 Table for all alternative assumptions explored). The assumption which reduced the estimated cost by the largest amount (-£14,123,076) was that only half of the increase in the number of inductions of labour observed were associated with the SBL care bundle (i.e. an increase of 10% rather than 20%). Including the cost of staff time to complete training courses associated with Elements 2 and 4 of the SBL care bundle increased the estimated cost by the largest amount (+£30,807,840).

Table 6. Alternative assumptions for costs associated with the SBL care bundle (total costs across the whole of England).

Alternative assumptions Change in cost versus base case† Total cost
10% increase in induction rate (versus ~20% observed) £14,123,076 lower £78,993,574
No direct implementation costs £3,650,357 lower £89,466,293
50% of maternity units use GAP software (versus 100%) £195,500 lower £92,921,150
Include cost for 5% of births to attend antenatal clinic with perceived RFM (£75.15/visit) (versus no visit) £2,569,296 higher £95,685,946
Include cost of increased rate of elective Caesarean sections (£3,438.12/delivery) (versus assume all would have been normal births (£1704.50/delivery)) £26,711,019 higher £119,827,669
Include cost of staff time to complete training courses (Element 2: £9,351,300; Element 4: £21,456,540 £30,807,840 higher £123,924,491

The total cost in the base case estimate was £93,116,650.

As reported above, the stillbirth rate was 0.84/1,000 births lower in the participating Trusts after SBL care bundle was implemented than before. Applying this to the number of births in England in 2015/16 (n = 666,052), an estimated 559 stillbirths per year may have been avoided. Using the primary estimate of the cost of the SBL care bundle (£93,116,650), this equates to £166,577 per stillbirth avoided. However, this figure should be interpreted with caution because it is not possible to determine the proportion of either the increase in secondary resource use or the reduction in stillbirths that are directly attributable to the SBL care bundle.

Discussion

This evaluation of the SBL care bundle found that implementation of the elements was variable, but increased from baseline levels in all early adopter sites. Over the same time frame stillbirth rates fell in the participating maternity units by 20% from 4.2 to 3.4 per 1,000 live births. This rate of reduction was greater than seen across the whole of England over the same period which reduced from 4.2 to 3.7 per 1,000 births from 2013–2017 (4.2 to 3.8 per 1,000 births in units not included in this evaluation) [19]. Data from MBRRACE from participating units suggests that the decrease in intrapartum stillbirths was particularly dramatic, falling from 0.32 per 1,000 births in 2013 to 0.06 per 1,000 births in 2016 (RR 0.18, 95% CI 0.08, 0.45) [3,20]. There were also important changes in secondary outcomes including a reduction in spontaneous vaginal births, increase in preterm births, Caesarean sections, ultrasound scans, and admissions to the neonatal unit. Due to the variation in implementation strategies, phasing and timing we were not able to identify a “step” in our time series analysis which would have suggested a direct association between implementation of the care bundle and the observed reduction in stillbirth or changes in secondary outcomes. However, the degree of implementation was related to important process measures including plotting of fetal growth and assessment of intrapartum fetal heart rate monitoring.

Strengths and limitations

This evaluation was strengthened by the adherence to a published protocol which used stillbirth as its primary outcome rather than a surrogate measure as often used in this area [11]. The evaluation was conducted in 19 different maternity units reflecting the diversity of UK maternity units and included approximately 14% of the births in the UK. The data presented here represent the major component of the Saving Babies’ Lives Project Impact and Results Evaluation (SPiRE project) which also included analysis of clinical practice guidelines and service-user and staff views to provide a holistic view of the impact of implementing the SBL care bundle. The results of the other components are reported elsewhere [21].

This study is limited by it’s before-and after study design which was employed pragmatically as the care bundle and its implementation were planned before the evaluation project was commissioned. The degree of implementation was self-reported by participating trusts which may not have accurately reflected the degree of implementation in the clinical service. Furthermore, the variation in levels, phasing, and strategies of implementation meant that there was no discrete moment within or across Trusts where a change in practice could be determined. The use of routinely collected data was both a strength and a limitation of the study. The use of routinely collected data allowed the project to achieve the necessary large sample size and to be undertaken in a comparatively short-time frame, but the use of these data were frequently challenging due to variation in codes and coding strategies employed by individual Trusts. Furthermore, routine data may include recognised coding errors in maternity health episode statistics [22], but as this would affect both the before and after time periods in this analysis the impact of this may be minimal. In some cases, this meant that data on certain items were excluded for some or all Trusts e.g. admission to neonatal unit and rate of hypoxic-ischaemic encephalopathy. This also meant that it was not possible to include costs (or potential cost-savings) associated with these items in the economic evaluation.

Meaning of the study: Possible explanations and implications for clinicians and policymakers

Reducing stillbirths (alongside reducing maternal deaths, neonatal deaths, and brain injuries) is an explicit priority of the UK government, with a target to reduce such events by 50% by 2030 and by 20% by 2020. Achieving this aim will require an annual rate of reduction for stillbirth of 3.3%, significantly greater than the 1.4% reported between 2000–15 [2]. If maintained, the annual rate of reduction described in the study sites (~5%) would be sufficient to achieve this ambitious target and represents the most rapid reduction in stillbirth rates in over 20 years and is on target to achieve the national ambition to halve the rate.

In common with earlier national care bundles in perinatal care (e.g. Necrotising Enterocolitis Care Bundle) this evaluation has demonstrated clear improvements in process outcomes, but it was more challenging to identify changes in element-specific clinical outcomes and relate these to the degree of implementation [23]. Although this evaluation was not able to determine whether implementation of the SBL care bundle or any individual element was associated with the observed reduction in stillbirth, the association is plausible. Detection of SGA infants, the strongest risk factor for stillbirth in the UK [24,25], improved by 59% and use of ultrasound scanning, the principal screening method for SGA infants increased by 24%. Importantly, increased frequency of ultrasound scanning was inversely associated with stillbirth, suggesting that a pathway of increased detection of SGA may reduce stillbirth. Unfortunately, causes of stillbirth, particularly fetal growth restriction, are poorly recorded in routinely collected data which prevents analysis to determine whether there has been a reduction in stillbirths from fetal growth restriction [26].

Unanswered questions and future research

Any argument proposing a link between implementation of SBL and the outcome measures must be weighed against the change in outcomes which were not associated with the SBL care bundle. For example, the 20% increase in elective Caesarean section, which is unlikely to relate to implementation of the SBL care bundle as it contains no recommendations about Caesarean section, is more likely to reflect changes in guidance from the National Institute of Health and Care Excellence published in 2011 [27]. In addition to changes in national policy, we were not able to identify specific initiatives which may have been implemented in participating Trusts contemporaneously. As the SBL care bundle continues to be rolled-out in UK maternity units further evaluation needs to be planned to identify potential causal effects on stillbirth and other clinical outcomes.

Stillbirths are relatively rare events in the UK therefore large, good-quality, datasets are critical to informing efforts to reduce the stillbirth rate. Health policy makers should consider the evaluation of healthcare programmes prior to their implementation, in order that the most robust evaluation possible can be incorporated to ascertain its effects on process and clinical outcomes. The AFFIRM study, which prospectively evaluated increased maternal awareness and staff education about RFM (i.e. Element 3 of the SBL care bundle) [28], demonstrated how a stepped-wedge cluster design can be used effectively in this context.

The analysis presented here provides information about the average effect of implementation of the care bundle across the 19 Trusts. However, we were not able to explore the reasons for the variation in levels of implementation between sites, thus further research is needed to explore the origins of variation seen in different settings. Analysis of clinical practice guidelines relating to the SBL care bundle in participating maternity units found wide variation in their quality [21]. An ethnographic study of a UK maternity unit with a strong safety record (which was not part of this evaluation) described six mechanisms in place to enhance safety including: clearly articulated, constantly reinforced standards of practice, behaviour and ethics and structural influences on mechanisms for safety (e.g. staffing levels and financial infrastructure) [29]. Thus, we hypothesise that influences accounting for variable implementation may include: human factors, leadership, availability of up to date, accurate clinical practice guidelines and sufficient resource to implement them. These merit exploration in future analyses and the information can then be used to inform future quality improvement programmes.

While the resources required to implement the SBL care bundle may seem large, they should be viewed from a national perspective. In 2014/15 approximately £2.5bn was spent in the NHS on maternity services (with 664,399 births) and in 2016/17 obstetric claims handled by the NHS Litigation Authority accounted for £4.3bn of new claims reported. Based on figures for 2014/15, the maternity tariff per birth was approximately £3,760; the direct costs associated with SBL care bundle are estimated to account for £5 of this with secondary costs estimated at £135 per birth. As the majority of Trusts participating in the study reported using GROW software to produce customised growth charts the costs to do so were included in the estimated costs, however it should be noted that this software was not specified in the SBL care bundle and that alternatives could be used. It was not possible to collect data regarding some important resources relevant to the implementation of SBL care bundle, for example the impact of incorporating additional elements into routine antenatal appointments without increasing the duration of appointments, or the costs associated with NICU admissions, and so it is acknowledged that there is uncertainty around the estimated costs. Future economic analysis of the impact of the SBL care bundle or similar initiatives should also consider the health and social care costs of stillbirth (estimated as £13.1M/year in 2018) [30], which are greater than for a live birth and also extend into pregnancies after stillbirth [31].

Conclusion

Prior to the launch of the SBL care bundle the UK stillbirth rate was 24th out of 49 HICs and the annual rate of reduction was in the lowest third. Although adoption of the SBL care bundle was variable, all sites implemented elements to some degree. In the same time frame, process outcomes improved and stillbirth rates in the early adopter units fell faster than national rates. However, changes in care had important secondary effects particularly with regard to increased obstetric intervention and consequent resource requirements. This assessment has provided an important insight into the need for evaluation to be planned at the same time as the implementation of large-scale initiatives to ensure that the opportunity to collect data to inform the ongoing development of care is maximised.

Supporting information

S1 Checklist. STROBE statement—checklist of items that should be included in reports of cohort studies.

(DOCX)

S1 Fig. Implementation of elements of the Saving Babies Lives care bundle.

A) Average implementation of all elements at different time frames of the project. B) Level of implementation of each elements at the post-implementation assessment. The total element scores vary due to different number of components in each Element. Element 1: Reducing smoking in pregnancy (4 components), Element 2: Risk assessment and surveillance for fetal growth restriction (5 components), Element 3: Raising awareness of reduced fetal movements (2 components) and Element 4: Promoting effective fetal monitoring in labour (5 components) Red = <50% of element implemented, Orange = 51–75% of element implemented, Green = >75% of element implemented. Republished from Saving Babies’ Lives Project Impact and Results Evaluation (SPiRE): A mixed methodology study under a CC BY license, with permission from the University of Manchester, original copyright 2018.

(TIF)

S2 Fig. Average total number of ultrasound scans performed per pregnancy.

Across participating sites pre and post implementation of the Saving Babies Lives care bundle demonstrating a 24% increase in the number of ultrasound scans performed. Republished from Saving Babies’ Lives Project Impact and Results Evaluation (SPiRE): A mixed methodology study under a CC BY license, with permission from the University of Manchester, original copyright 2018.

(TIF)

S1 Table. Sensitivity analysis and alternative costs for health economic analysis.

(DOCX)

S1 File. Questionnaire for women to complete after giving birth.

(PDF)

S2 File. Questionnaire regarding staff views and experiences of the SBL care bundle.

(PDF)

S3 File. Characteristics of participants in the questionnaire for health care professionals.

(PDF)

Acknowledgments

Holly Reid who participated in the study design. Participants, research midwives and members of professional bodies and charity organisations who participated in the stakeholder groups (Tommy’s, RCM, PI, BAPM, RCOG, Sands, Tamba, MAMAs, BMFMS). The authors would like to thank staff from the participating NHS Trusts for providing data and undertaking audits: Barnsley Hospital NHS Foundation Trust, Birmingham Women’s and Children’s NHS Foundation Trust, Countess of Chester Hospital NHS Foundation Trust, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Gateshead Health NHS Foundation Trust, Liverpool Women’s NHS Foundation Trust, Manchester University NHS Foundation Trust, Norfolk and Norwich University Hospitals NHS Trust, North Cumbria University Hospitals NHS Trust, Oxford University Hospitals NHS Trust, Plymouth Hospital NHS Trust, Royal United Hospitals Bath NHS Foundation Trust, Sherwood Forest Hospitals NHS Foundation Trust, St Helens and Knowsley Teaching Hospitals NHS Trust, Taunton and Somerset NHS Foundation Trust, Mid Yorkshire Hospitals NHS Trust, Royal Devon & Exeter NHS Foundation Trust, University Hospitals of Morecambe Bay NHS Foundation Trust and York Teaching Hospital NHS Foundation Trust.

Data Availability

There is no ethical approval in place to share data from participating Trusts. Anonymised data from staff and patient questionnaires can be made available subject to appropriate confidentiality agreements between participating organisations. Investigators wishing to obtain data should initially contact the Edgbaston Research Ethics Committee (edgbaston.rec@hra.nhs.uk).

Funding Statement

AH, EC and SR recieved funding for this work from NHS England. NHS England approved the research protocol but had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Still-Birth Definition Act 1992, Curr Law Statut Annot GB: Great Britain p. 1. [PubMed]
  • 2.Flenady V., et al., Stillbirths: recall to action in high-income countries. Lancet, 2016. 387(10019): p. 691–702. 10.1016/S0140-6736(15)01020-X [DOI] [PubMed] [Google Scholar]
  • 3.Manktelow B.M., et al., Perinatal Mortality Surveillance Report—UK Perinatal Deaths for births from January to December 2013. 2015, The Infant Mortality and Morbidity Group, Department of Health Sciences, University of Leicester.: Leicester. [Google Scholar]
  • 4.Manktelow B.M., et al., Perinatal Mortality Surveillance Report—UK Perinatal Deaths for births from January to December 2014. 2016, The Infant Mortality and Morbidity Group, Department of Health Sciences, University of Leicester.: Leicester. [Google Scholar]
  • 5.Heazell A.E., et al., Stillbirths: economic and psychosocial consequences. Lancet, 2016. 387(10018): p. 604–16. 10.1016/S0140-6736(15)00836-3 [DOI] [PubMed] [Google Scholar]
  • 6.Draper E.S., et al., MBRRACE-UK Perinatal Confidential Enquiry: Term, singleton, normally formed, antepartum stillbirth. 2015, The Infant Mortality and Morbidty Studies, Department of Health Sciences, University of Leicester: Leicester. [Google Scholar]
  • 7.Draper E.S., et al., MBRRACE-UK Perinatal Confidential Enquiry: Term, singleton, intrapartum stillbirth and intrapartum-related neonatal death. 2017, The Infant Mortality and Morbidty Studies, Department of Health Sciences, University of Leicester: Leicester. [Google Scholar]
  • 8.Flenady V., et al., Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet, 2011. 377(9774): p. 1331–40. 10.1016/S0140-6736(10)62233-7 [DOI] [PubMed] [Google Scholar]
  • 9.Confidential Enquiry into Stillbirths and Deaths in Infancy, 8th Annual Report, 1 January–31 December 1999. 2001, Maternal and Child Health Research Consortium: London.
  • 10.England NHS, Saving Babies Lives: a care bundle for reducing stillbirth. 2016, NHS England: London. [Google Scholar]
  • 11.Widdows K., et al., Saving babies’ lives project impact and results evaluation (SPiRE): a mixed methodology study. BMC Pregnancy Childbirth, 2018. 18(1): p. 43. 10.1186/s12884-018-1672-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Vieira M.C., et al., The DESiGN trial (DEtection of Small for Gestational age Neonate), evaluating the effect of the Growth Assessment Protocol (GAP): study protocol for a randomised controlled trial. Trials, 2019. 20(1): p. 154. 10.1186/s13063-019-3242-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.von Elm E., et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med, 2007. 4(10): p. e296. 10.1371/journal.pmed.0040296 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.R Core Team R: A language and environment for statistical computing. 2013, R Foundation for Statistical Computing: Vienna, Austria. [Google Scholar]
  • 15.Department of Health, National schedule of reference costs 2015–2016, D.o. Health, Editor. 2016.
  • 16.Curtis L.A. and Burns A. Unit Costs of Health and Social Care 2016. 2016; Available from: http://www.pssru.ac.uk. [Google Scholar]
  • 17.NHS Supply Chain. [cited 2017 June]; Available from: https://www.supplychain.nhs.uk/.
  • 18.Office of National Statistics, Births and Deaths in England and Wales 2016. 2017, Office of National Statistics: Fareham, Hampshire. [Google Scholar]
  • 19.Office for National Statistics. Births in England and Wales: summary tables (2017). 2018; Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/datasets/birthsummarytables.
  • 20.Draper E.S., et al., MBRRACE-UK Perinatal Mortality Surveillance Report, UK Perinatal Deaths for Births from January to December 2016 2018, The Infant Mortality and Morbidity Studies, Department of Health Sciences, University of Leicester.: Leicester. [Google Scholar]
  • 21.Lau Y.Z., et al., Assessment of the quality, content and perceived utility of local maternity guidelines in hospitals in England implementing the saving babies’ lives care bundle to reduce stillbirth. BMJ Open Qual, 2020. 9(2). 10.1136/bmjoq-2019-000756 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Harper G., Linkage of Maternity Hospital Episode Statistics data to birth registration and notification records for births in England 2005–2014: Quality assurance of linkage of routine data for singleton and multiple births. BMJ Open, 2018. 8(3): p. e017898. 10.1136/bmjopen-2017-017898 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.East of England Neonatal Network, The Necrotising Enterocollitis Care Bundle Legacy Document. 2015, East of England Neonatal Operational Delivery Network: Cambridge. [Google Scholar]
  • 24.Gardosi J., et al., Maternal and fetal risk factors for stillbirth: population based study. Bmj, 2013. 346: p. f108. 10.1136/bmj.f108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Heazell, A.E., et al., Going to sleep supine is a modifiable risk factor for late stillbirth–findings from the Midland and North of England Stillbirth Case-Control Study Bjog, 2017. Submitted.
  • 26.Higgins L.E., Heazell A.E.P., and Whitworth M.K., Persistent inaccuracies in completion of medical certificates of stillbirth: A cross-sectional study. Paediatr Perinat Epidemiol, 2018. 32(5): p. 474–481. 10.1111/ppe.12501 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.National Institute for Health and Care Excellence, Caesarean Section (CG162). 2011, National Institute for Health and Care Excellence: London. [Google Scholar]
  • 28.Norman J.E., et al., Awareness of fetal movements and care package to reduce fetal mortality (AFFIRM): a stepped wedge, cluster-randomised trial. Lancet, 2018. 392(10158): p. 1629–1638. 10.1016/S0140-6736(18)31543-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Liberati E.G., et al., How to be a very safe maternity unit: An ethnographic study. Soc Sci Med, 2019. 223: p. 64–72. 10.1016/j.socscimed.2019.01.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Campbell H.E., et al., Healthcare and wider societal implications of stillbirth: a population-based cost-of-illness study. BJOG, 2018. 125(2): p. 108–117. 10.1111/1471-0528.14972 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Mistry H., et al., A structured review and exploration of the healthcare costs associated with stillbirth and a subsequent pregnancy in England and Wales. BMC Pregnancy Childbirth, 2013. 13: p. 236. 10.1186/1471-2393-13-236 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Ju Lee Oei

28 Oct 2020

PONE-D-20-24240

Stillbirth rates, service outcomes and costs of implementing NHS England’s Saving Babies’ Lives care bundle in maternity units in England: a cohort study

PLOS ONE

Dear Dr. Heazell,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 12 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Ju Lee Oei

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study. Specifically, please ensure that you have discussed whether all data/samples were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data/samples from their medical records used in research, please include this information.

3. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a table of relevant demographic details, d) a statement as to whether your sample can be considered representative of a larger population, e) a description of how participants were recruited, and f) descriptions of where participants were recruited and where the research took place.

4. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

5. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere.

"This manuscript is original, but a portion of these data were presented previously in an archived report of the SPiRE evaluation which is available here –

https://www.manchester.ac.uk/discover/news/download/573936/evaluationoftheimplementationofthesavingbabieslivescarebundleinearlyadopternhstrustsinenglandjuly2018-2.pdf). "

Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

6. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Manuscript: PONE-D-20-24240

Stillbirth rates, service outcomes and costs of implementing NHS England’s Saving Babies’ Lives care bundle in maternity units in England: a cohort study

General comments

In this manuscript the authors describe a cohort study used to perform and in-depth evaluation of a national initiative to address stillbirth rates in the UK. Although necessarily pragmatic in design, this is a well-constructed and reported study. The reported finding of a reduction in stillbirth rates across participating sites that exceeds that reported nationally in the same timeframe will be of interest to a broad, international readership.

Specific comments

Abstract

• Line 42, p 3- ‘Implementation of the SBL care bundle increased over time in the majority of sites with associated improvements in process outcomes. This statement lacks clarity and needs re- wording.

Methods

• Line 114, p6- where authors describe method for scoring degree of implementation. What do you mean by totalled to give an implementation score for each element? Did each element have multiple components that were each scored then added or was there only one degree of implementation question per element? Was there any weighting given to certain components? i.e. some more important than others? It would be helpful for the reader to have clearly stated somewhere what ‘implementing’ element 1, 2, 3, 4, refers to (even though this may have been previously published).

• Line 162, p9- Was there a specific reason staff time to complete training was not included in costs, especially for externally-provided training? Why were cost associated with neonatal outcomes not included? eg admission to NICU

Discussion

• Line 267, p14- Authors mention a decrease in SB rate for ‘whole of England’, how much of this decrease can be accounted for by the trusts included in this evaluation? It may be worthwhile comparing SB rate reduction for ‘early adopters’ and ‘all other’ sites as separate groups as well as total ‘whole of England’ reduction?

Limitations

• Could the authors provide comment on whether self-reported degree of implementation as described is a limitation of the study and how this may have contributed to challenges if any with interpretation of results.

General

• Are the authors able to offer any further insights as to why adoption of the bundle was variable across sites and what unit characteristics made a ‘high degree’ implementer? E.g. influence of leadership, resources, other?

• It would be of value to understand maternity staff attitudes towards the ‘bundle approach’, satisfaction with the way it was implemented and how this might have influenced process outcomes. Were there additional results from the survey of staff that are not reported here that might describe this?

• Consider replacing the word “ patients” with “ women” and “ deliveries” with “births” throughout.

Tables and Figures

• Table 3. – In source column consider replacing ‘Patient’ with ‘women”

• Supplementary Figure 1- Heading check grammar- ‘implantaion’? Could the authors explain for section B why the x-axis has a different scale for each element? This goes back to previous comment in methods, it is unclear how you are calculating the score for each element. Could you also please explain why site K has an overall score of 0% yet does have scores for each element?

• Given element 4 is intrapartum monitoring it would be helpful to see SB rate broken down into antepartum vs intrapartum to further explain changes in SB rate due to implementation of element 4.

Reviewer #2: Thanks for allowing me to review your manuscript. I have several comments and questions.

1. Can you provide more details about the process for selecting the 19 NHS trusts involved in this evaluation? How was it that a trust with an implementation score of 0 was selected?

2. I found the economic analysis difficult to follow due to the number of assumptions made. In particular, it seems that all of the increased interventions are costed as 'additional costs' whereas it may also be that increases in certain interventions such as induction of labour and caesarean section actually save money in terms of reducing other adverse outcomes. I do wonder if the economic analysis is worthy of a separate paper, which would then allow a much more comprehensive review of the costs of this bundle implementation.

3. The data presented gives rates of 'total stillbirths' and 'term stillbirths' but it would also be of interest to see how rates changed at lower gestations. It might be expected that the interventions would have a major impact on late gestation stillbirth but it appears that there have been come changes at earklier gestations as well. Can you provide that information? I am sure it would be of interst to the readers.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: David Ellwood

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Apr 19;16(4):e0250150. doi: 10.1371/journal.pone.0250150.r002

Author response to Decision Letter 0


3 Feb 2021

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

The manuscript has been formatted to match PLOS ONE’s style requirements.

2. In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study. Specifically, please ensure that you have discussed whether all data/samples were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data/samples from their medical records used in research, please include this information.

All data were fully anonymized before analysis. Participants in the online survey were asked to indicate their consent to participation in their response.

3. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a table of relevant demographic details, d) a statement as to whether your sample can be considered representative of a larger population, e) a description of how participants were recruited, and f) descriptions of where participants were recruited and where the research took place.

The Methods section includes the date ranges for specific components of the study. Table 1 describes the characteristics of the maternity units (NHS Trusts) that participated in the study. No demographic data for individual participants were collected. We have described how participating units were selected and where the research took place.

4. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

The questionnaire for women who gave birth at participating Trusts and the questionnaire for staff working at participating trusts have been included as supplementary files.

5. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere.

"This manuscript is original, but a portion of these data were presented previously in an archived report of the SPiRE evaluation which is available here –

https://www.manchester.ac.uk/discover/news/download/573936/evaluationoftheimplementationofthesavingbabieslivescarebundleinearlyadopternhstrustsinenglandjuly2018-2.pdf). "

Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

This work was published on the University of Manchester website and a limited number of printed copies but was not peer-reviewed.

6. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

We did not ask participating units whether we could share the data they provided to the study. Therefore, we are not able to share it legally or under the terms of the research ethics approval granted for this study. Data requests should be sent to the Chief Investigator who can then approach the research ethics committee to determine whether access can be facilitated.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Reviewer #1:

General comments

In this manuscript the authors describe a cohort study used to perform and in-depth evaluation of a national initiative to address stillbirth rates in the UK. Although necessarily pragmatic in design, this is a well-constructed and reported study. The reported finding of a reduction in stillbirth rates across participating sites that exceeds that reported nationally in the same timeframe will be of interest to a broad, international readership.

Specific comments

Abstract

• Line 42, p 3- ‘Implementation of the SBL care bundle increased over time in the majority of sites with associated improvements in process outcomes. This statement lacks clarity and needs re- wording.

This statement has been re-worded and now reads “Implementation of the SBL care bundle increased over time in the majority of sites. Implementation was associated with improvements in process outcomes.” (lines 42-44)

Methods

• Line 114, p6- where authors describe method for scoring degree of implementation. What do you mean by totalled to give an implementation score for each element? Did each element have multiple components that were each scored then added or was there only one degree of implementation question per element? Was there any weighting given to certain components? i.e. some more important than others? It would be helpful for the reader to have clearly stated somewhere what ‘implementing’ element 1, 2, 3, 4, refers to (even though this may have been previously published).

The section on the implementation scoring has been revised for clarity. Units were asked to report a score for the implementation for each component of each element (ranked 0-3). These were then added to give the total for each element which is presented in Supplementary Figure 1. As some elements had different numbers of components the overall implementation was computed as the mean of each element expressed as a percentage of the total score (now edited lines 122-125). Thus all components were equally weighted within each element, and each element equally weighted in the overall implementation score. The authors have edited the manuscript to clarify what element 1, 2, 3 and 4 refers to in the introduction section (Lines 71-75) and also added the word “element” to caption of sup figure 1 to make this more explicit.

• Line 162, p9- Was there a specific reason staff time to complete training was not included in costs, especially for externally-provided training? Why were cost associated with neonatal outcomes not included? E.g. admission to NICU.

The time to complete training was not included in the primary estimate of costs due to the assumption that in-house training would be part of continuing professional development for staff. However, this has now been included in the sensitivity analyses reported in Table 6. Data on neonatal admissions were not included in the evaluation because of significant inconsistencies between data supplied from different providers which also meant that the associated costs could not be included in the economic analysis. The authors recognise that this is a limitation of the study (lines 335-336).

Discussion

• Line 267, p14- Authors mention a decrease in SB rate for ‘whole of England’, how much of this decrease can be accounted for by the trusts included in this evaluation? It may be worthwhile comparing SB rate reduction for ‘early adopters’ and ‘all other’ sites as separate groups as well as total ‘whole of England’ reduction?

The stillbirth rate for the whole of England across the duration of this study (as derived from central MBRRACE data) was 4.22 per 1,000 births in 2013 to 3.74 per 1,000 births in 2017. In participating units the rates fell from 4.23 per 1,000 births in 2013 to 3.40 per 1,000 births in 2017, in comparison units not participating in this evaluation the rates were 4.21 per 1,000 births in 2013 and 3.8 per 1,000 births in 2017. We have included this information in the discussion section. However, there were a number of sites not included in this evaluation that were implementing aspects of the SBL care bundle and one site (site S) within the evaluation who had very limited implementation. Therefore, we do not think it is appropriate to view this as a comparison between early adopters and all other sites.

Limitations

• Could the authors provide comment on whether self-reported degree of implementation as described is a limitation of the study and how this may have contributed to challenges if any with interpretation of results.

The authors agree with the reviewer that self-reported degree of implementation is a limitation of the study and this has been added to the limitations section of the study (lines 323-325). However, the process measures do give us an objective measure of implementation.

General

• Are the authors able to offer any further insights as to why adoption of the bundle was variable across sites and what unit characteristics made a ‘high degree’ implementer? E.g. influence of leadership, resources, other?

Unfortunately we did not collect information about the leadership structure or resources of individual Trusts to be able to make a valid judgement about whether these factors affected the degree of implementation of the care bundle across sites. We collected some information from staff about their perceptions of safety in the maternity unit where they work. This has been added to the manuscript. We have added this as an area for future work in the discussion section of the manuscript (lines 379-381).

• It would be of value to understand maternity staff attitudes towards the ‘bundle approach’, satisfaction with the way it was implemented and how this might have influenced process outcomes. Were there additional results from the survey of staff that are not reported here that might describe this?

We collected data from staff (n=1,064) regarding their views about the care bundle. We have previously reported staff views about clinical practice guidelines in their units (Lau et al. BMJ Open Quality 2020;9:e000756) and have not repeated these findings here. We have included information about staff views about the care bundle including the demand for ultrasound scanning, the stillbirth rate, induction rate and number of Caesarean sections in the results section. We have also included staff views about safety in their maternity unit (lines 261-267).

• Consider replacing the word “patients” with “women” and “deliveries” with “births” throughout.

Patients have been replaced with women and deliveries have been replaced with births throughout the manuscript.

Tables and Figures

• Table 3. – In source column consider replacing ‘Patient’ with ‘women”

Patient has been replaced by women in the source column of Table 3.

• Supplementary Figure 1- Heading check grammar- ‘implantaion’? Could the authors explain for section B why the x-axis has a different scale for each element? This goes back to previous comment in methods, it is unclear how you are calculating the score for each element. Could you also please explain why site K has an overall score of 0% yet does have scores for each element?

The heading has been altered to read “implementation”. An explanation has been added to explain why the x-axis is different for each element in the methods section. This has been reiterated in the figure legend. In figure A) implementation at baseline, implementation date and post-implementation is shown. In Figure B, the breakdown for the different elements is given at the post-implementation time point is shown. This is stated in the legend. The x-axis for the charts in section A has been altered to read % Implementation score.

• Given element 4 is intrapartum monitoring it would be helpful to see SB rate broken down into antepartum vs intrapartum to further explain changes in SB rate due to implementation of element 4.

Unfortunately we did not collect information on the timing of stillbirth so are not able to present the intrapartum stillbirth rate in our manuscript. However, the statistics from MBRRACE demonstrate that the intrapartum stillbirth rate fell from 0.32 per 1,000 births in participating units in 2013 to 0.06 per 1,000 births in 2016 (Relative risk 0.18, 95% CI 0.08, 0.45). As these data were not obtained from our data we have not included this information in the results section but have added it to the discussion section of the manuscript (lines 303-305).

Reviewer #2:

Thanks for allowing me to review your manuscript. I have several comments and questions.

1. Can you provide more details about the process for selecting the 19 NHS trusts involved in this evaluation? How was it that a trust with an implementation score of 0 was selected?

All Trusts that were deemed “early adopters” of the SBLCB in 2015 were eligible to take part; these were sites that completed the 2015 NHS England Tracker Survey indicating that they were implementing the SBLCB. Initially, Trusts were selected to take part in the evaluation to compare outcomes in providers reporting full, partial or low implementation stages as reported in the Tracker Survey, But at the time of the study in 2016 most Trusts had increased their implementation so the original study design of full, partial, low was not possibleUnits were purposively sampled to provide a geographically distributed sample throughout England and a mixture of Trusts with different numbers of births and levels of neonatal care. Units from London were not included as they were participating in a stepped-wedge cluster trial of implementation of the Growth Assessment Protocol (Trials 2019 Mar 4;20(1):154. doi: 10.1186/s13063-019-3242-6). The Trust (S) had an implementation score of 0 at baseline which improved to 40% post-implementation, so although the implementation from this site was far from that anticipated, some aspects of the SBL care bundle had been introduced.

Information regarding the selection of sites has been included in the methods section (lines 88-92).

2. I found the economic analysis difficult to follow due to the number of assumptions made. In particular, it seems that all of the increased interventions are costed as 'additional costs' whereas it may also be that increases in certain interventions such as induction of labour and caesarean section actually save money in terms of reducing other adverse outcomes. I do wonder if the economic analysis is worthy of a separate paper, which would then allow a much more comprehensive review of the costs of this bundle implementation.

We have rephrased the reporting of the results of the economic analysis to make it easier to follow. Due to the pragmatic and post hoc nature of the evaluation it was necessary to make a number of assumptions in order to estimate the costs associated with the care bundle as it was not possible to collect additional data. This also means that a more comprehensive review of the costs is not possible and so we feel that this combined paper is appropriate. We agree that there may have been some downstream cost-savings associated with fewer adverse outcomes, for example if there were fewer NICU admissions, however data were not available to quantify these impacts and so it was not possible to include them in this analysis. This has been added as a limitation in the discussion (lines 335-336).

3. The data presented gives rates of 'total stillbirths' and 'term stillbirths' but it would also be of interest to see how rates changed at lower gestations. It might be expected that the interventions would have a major impact on late gestation stillbirth but it appears that there have been come changes at earlier gestations as well. Can you provide that information? I am sure it would be of interest to the readers.

We do not have sufficiently detailed data to calculate the stillbirth rate for individual gestations or groups of gestational ages, but we are able to divide total stillbirths into “term stillbirths” and “preterm stillbirths”. The rate of term stillbirth decreased from 1.9 per 1,000 births pre-intervention to 1.4 per 1,000 births post-intervention (Relative Risk 0.77, p=0.005) and the rate of pre-term stillbirth decreased from 2.3 per 1,000 births to 1.9 per 1,000 births (Relative Risk 0.82, p=0.014). We have added this information to the manuscript to emphasise that there were reductions in both term and preterm stillbirths (lines 213-215).

Attachment

Submitted filename: Response to Reviewer_SBLCB_Evaluation_Final.docx

Decision Letter 1

Ju Lee Oei

9 Mar 2021

PONE-D-20-24240R1

Stillbirth rates, service outcomes and costs of implementing NHS England’s Saving Babies’ Lives care bundle in maternity units in England: a cohort study

PLOS ONE

Dear Dr. Heazell,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process, including reviewer 3 who has requests for clarification of reporting, which I think can be answered easily. 

Please submit your revised manuscript by Apr 23 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Ju Lee Oei

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

Reviewer #3: This is a well-conducted study; however its reporting does not follow the appropriate reporting guidelines, and I am unable to make out a number of key features; for example:

- it is unclear whether the investigators obtained individual/participant level data or whether the data was collected already aggregated at trust or hospital hospital-level. I understand that it could have been a mix of these for different variables e.g. individual-level outcomes and trust-level covariates, however, even this needs to be made clear for the various variables when they are described.

- the number of units studied should be reported very clearly when indicating the size of this study. For example, the abstract describes this as a retrospective cohort study of 463,630 births in 19 trusts and mentions 1,658 audits, an surveys of 2085 users and 1,064 health professionals, but it is still not quite clear which of these units the outcomes reported pertain to; for example, did you obtain stillbirth events for each particpant or did you obtain them aggregated at hospital/trust level? It is also not clear how the numbers of units break down over the various times the assessments relate to.

- the key variables for this analysis are not clearly described; for example, what were the outcomes and how were they defined/measured and at what level (individual? aggregated at higher level? repeated over time?); what was the main exposure variable and how was it defined? any covariates and how they were measured/defined for the analysis?

- the approach to analysis is not clearly described. Without knowing what the outcome and explanatory variables were, or the units of analysis (individual?/trust?/hospital?), it is not possible to assess whether the models described were suitable i.e. appropriate for the outcome variables, level of aggregation, any hierarchical relationships in the data, assessing change etc. For instance, the RRs in Table 2 compare post- and pre- periods (however defined), but it is not clear whether the rates in those periods are obtained from a model on the outcomes of individual women, or a model on aggregated outcomes at hospital level across 19 trusts, or even aggregated outcomes at trust level. Furthermore, the results tables should present number of units of observation contributing to the pre- and the post- rates/proportions for each outcome, not just the overall totals as currently presented. Ideally, for the reporting of outcomes, assuming they are all rates, you should report the number of units (e.g. individuals), the number of events and the rate in the pre- and in the post- period, followed by the rate ratio, confidence intervals and p-value for the test of comparison of the two periods. Crude and adjusted rate ratios/CIs/p-values should be presented if unadjusted and adjusted models were used. For all outcomes, please be clear about how they are aggregated; for example when the change in the number of women smoking is reported as 14.3% to 11.8%, was this pooled across all women in the two periods or was this first aggregated at hospital or trust level and then pooled and compared? The answer to this question is important because it makes a difference in how the variability of the outcome is determined and whether this is indeed a statistically significant difference or not (this also applies to how the rate ratios are calculated all through).

Overall, I would recommend a clearer overall reporting (especially of the methods and results) to be consistent with the reporting guidelines appropriate for this study, and a more detailed description of the statistical methods to enable assessment of their suitability and potential replication by authors of similar studies.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Apr 19;16(4):e0250150. doi: 10.1371/journal.pone.0250150.r004

Author response to Decision Letter 1


26 Mar 2021

We would like to thank the reviewers for their comments on our manuscript. We note that Reviewer#2 has no further comments on our manuscript.

Reviewer #3: This is a well-conducted study; however its reporting does not follow the appropriate reporting guidelines, and I am unable to make out a number of key features; for example:

The study report was written according to the STROBE checklist. This was already uploaded as a supporting document to the PLoSOne website. We have included this information in the manuscript to ensure that readers are aware that we followed reporting guidelines (line 102).

- it is unclear whether the investigators obtained individual/participant level data or whether the data was collected already aggregated at trust or hospital hospital-level. I understand that it could have been a mix of these for different variables e.g. individual-level outcomes and trust-level covariates, however, even this needs to be made clear for the various variables when they are described.

The reviewer is correct that we used a mix of different methods of data collection for individual components of the analysis. We described these in the published protocol all these details are available to readers. We state in the methods the three different data structures

- Implementation data at Trust level (i.e. already aggregated data) (line 122)

- Clinical outcomes and smoking as monthly counts per centre (line 107ff)

- Audit data at specified time points (lines 111-114)

- Post-partum patient questionnaire (line 115 - 116). We have now clarified that this individual questionnaire data was only obtained in the post-intervention period (line 114).

Table 3 gives the source of data for each outcome. We have now made it explicit that “women” in table 3 refers to the questionnaire.

- the number of units studied should be reported very clearly when indicating the size of this study. For example, the abstract describes this as a retrospective cohort study of 463,630 births in 19 trusts and mentions 1,658 audits, an surveys of 2085 users and 1,064 health professionals, but it is still not quite clear which of these units the outcomes reported pertain to; for example, did you obtain stillbirth events for each participant or did you obtain them aggregated at hospital/trust level? It is also not clear how the numbers of units break down over the various times the assessments relate to.

Full details of the sources of each data are provided in the published protocol. The information on the numbers of units and women providing data for each outcome is provided in tables 2 and 3. The survey of women and questionnaires from health professionals were obtained from all 19 participating units. Data regarding the characteristics of staff participants has been added as a supplementary file (S3). The data regarding stillbirths were obtained and then aggregated at unit level.

Line 107 states: “outcome data was collected from routine electronic clinical data held in Trust data repositories… monthly aggregate totals”.

- the key variables for this analysis are not clearly described; for example, what were the outcomes and how were they defined/measured and at what level (individual? aggregated at higher level? repeated over time?); what was the main exposure variable and how was it defined? any covariates and how they were measured/defined for the analysis?

The protocol provided detailed information on the data sources and is publicly available and cited in the manuscript. It is clearly stated that all outcome data is aggregated to site/month, although for practical purposes some variables were aggregated by the analysis team rather than the data provider. The main exposure variable is the SBL intervention as stated in the title and the first line of the method section (lines 83-84). No covariates are mentioned as there were none, other than the Trust (line 137)

- the approach to analysis is not clearly described. Without knowing what the outcome and explanatory variables were, or the units of analysis (individual?/trust?/hospital?), it is not possible to assess whether the models described were suitable i.e. appropriate for the outcome variables, level of aggregation, any hierarchical relationships in the data, assessing change etc. For instance, the RRs in Table 2 compare post- and pre- periods (however defined), but it is not clear whether the rates in those periods are obtained from a model on the outcomes of individual women, or a model on aggregated outcomes at hospital level across 19 trusts, or even aggregated outcomes at trust level.

We argue that the analytical approach is clear in the manuscript. The main analyses are clearly stated to be based on data aggregated at the trust/month level (lines 134-135). The estimates are defined clearly as estimates 2 years before and 2 years post the nominal implementation date (Line 138) from a linear trend model (line 137). For example, the data supplied by the participating units included the number of stillbirths, number of births etc. so in some cases data were aggregated by the team.

Furthermore, the results tables should present number of units of observation contributing to the pre- and the post- rates/proportions for each outcome, not just the overall totals as currently presented. Ideally, for the reporting of outcomes, assuming they are all rates, you should report the number of units (e.g. individuals), the number of events and the rate in the pre- and in the post- period, followed by the rate ratio, confidence intervals and p-value for the test of comparison of the two periods.

Although the data analysed were obtained from individual units the relevant number is the number of women in the model (i.e. the totals that are presented), and the RR presented is based on the slope over time – converted to a pre-post RR for ease of interpretation.

Crude and adjusted rate ratios/CIs/p-values should be presented if unadjusted and adjusted models were used.

There were no adjusted models for the primary analyses (other than the inclusion of Trust). The secondary analyses by implementation status did include covariates, but as this was a secondary analysis we believe that adding unadjusted results would confuse rather than enhance the manuscript. This was done as a sensitivity analysis and made no substantive difference to the result.

For all outcomes, please be clear about how they are aggregated; for example when the change in the number of women smoking is reported as 14.3% to 11.8%, was this pooled across all women in the two periods or was this first aggregated at hospital or trust level and then pooled and compared? The answer to this question is important because it makes a difference in how the variability of the outcome is determined and whether this is indeed a statistically significant difference or not (this also applies to how the rate ratios are calculated all through).

Smoking data is (see table 3) derived from two sources. The Electronic data is aggregated on the per trust per month basis as described above. The women’s questionnaire data was analysed in the same way as the audit data (This has been clarified by adding “and women’s questionnaire data” to line 145). With specific regard to the reviewer’s comment on the change in frequency of smoking, 14.3% is the point estimate 2 years prior to the implementation of the SBL care bundle and 11.8% is at the assessment point 2 years after the implementation. These data were obtained by calculating the pooled proportion of women who smoked aggregated from the individual unit data.

Overall, I would recommend a clearer overall reporting (especially of the methods and results) to be consistent with the reporting guidelines appropriate for this study, and a more detailed description of the statistical methods to enable assessment of their suitability and potential replication by authors of similar studies

We believe all the information requested was available in brief in the manuscript and in detail in the published protocol. A few details have been clarified in the manuscript where these were missing. We have adhered to the STROBE reporting guidleines.

Attachment

Submitted filename: Response_to_Reviewer_260321.docx

Decision Letter 2

Ju Lee Oei

1 Apr 2021

Stillbirth rates, service outcomes and costs of implementing NHS England’s Saving Babies’ Lives care bundle in maternity units in England: a cohort study

PONE-D-20-24240R2

Dear Dr. Heazell,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ju Lee Oei

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Acceptance letter

Ju Lee Oei

7 Apr 2021

PONE-D-20-24240R2

Stillbirth rates, service outcomes and costs of implementing NHS England’s Saving Babies’ Lives care bundle in maternity units in England: a cohort study

Dear Dr. Heazell:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ju Lee Oei

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. STROBE statement—checklist of items that should be included in reports of cohort studies.

    (DOCX)

    S1 Fig. Implementation of elements of the Saving Babies Lives care bundle.

    A) Average implementation of all elements at different time frames of the project. B) Level of implementation of each elements at the post-implementation assessment. The total element scores vary due to different number of components in each Element. Element 1: Reducing smoking in pregnancy (4 components), Element 2: Risk assessment and surveillance for fetal growth restriction (5 components), Element 3: Raising awareness of reduced fetal movements (2 components) and Element 4: Promoting effective fetal monitoring in labour (5 components) Red = <50% of element implemented, Orange = 51–75% of element implemented, Green = >75% of element implemented. Republished from Saving Babies’ Lives Project Impact and Results Evaluation (SPiRE): A mixed methodology study under a CC BY license, with permission from the University of Manchester, original copyright 2018.

    (TIF)

    S2 Fig. Average total number of ultrasound scans performed per pregnancy.

    Across participating sites pre and post implementation of the Saving Babies Lives care bundle demonstrating a 24% increase in the number of ultrasound scans performed. Republished from Saving Babies’ Lives Project Impact and Results Evaluation (SPiRE): A mixed methodology study under a CC BY license, with permission from the University of Manchester, original copyright 2018.

    (TIF)

    S1 Table. Sensitivity analysis and alternative costs for health economic analysis.

    (DOCX)

    S1 File. Questionnaire for women to complete after giving birth.

    (PDF)

    S2 File. Questionnaire regarding staff views and experiences of the SBL care bundle.

    (PDF)

    S3 File. Characteristics of participants in the questionnaire for health care professionals.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewer_SBLCB_Evaluation_Final.docx

    Attachment

    Submitted filename: Response_to_Reviewer_260321.docx

    Data Availability Statement

    There is no ethical approval in place to share data from participating Trusts. Anonymised data from staff and patient questionnaires can be made available subject to appropriate confidentiality agreements between participating organisations. Investigators wishing to obtain data should initially contact the Edgbaston Research Ethics Committee (edgbaston.rec@hra.nhs.uk).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES